Human milk Oligosaccharides -a new generation of digestive care for infants, children and adults
Glycom is a Danish biotechnology company dedicated to the scientific, clinical and commercial development of Human Milk Oligosaccharides for a broad range of applications.
Glycom was acquired by DSM in 2020 for €265 millions. PreSeed Ventures were the first professional investor to support the company and kept shares in the company throughout the entire journey - from the early days to exit.
Since the early 00s Glycom's primary focus has been to make Human Milk Oligosaccharides (HMOs) widely available for human consumption. HMOs are unique microbiome nutrients natural to the human body as they are identical in structure to those present in mother’s milk and similar to those in the protective lining of the digestive tract. At Glycom, they cracked the code of manufacturing these unique compounds, which are authorized as safe by EFSA and FDA.